NEWS

抄読会論文
  • Interstitial pneumonia with autoimmune features and histologic usual interstitial pneumonia treated with anti-fibrotic versus immunosuppressive therapy

    2024.02.19 | 抄読会論文
    抄読会要旨 岡林比呂子...
  • Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer

    2023.11.1 | 抄読会論文
    抄読会要旨 今村光佑...
  • Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

    2023.10.27 | 抄読会論文
    抄読会要旨 猪山慎治...
  • High yield of pleural cell-free DNA for diagnosis of oncogenic mutations in lung adenocarcinoma

    2023.10.12 | 抄読会論文
    抄読会要旨 木村俊貴...
  • Efzofitimod for the Treatment of Pulmonary Sarcoidosis

    2023.09.21 | 抄読会論文
    抄読会要旨 岡林比呂子...
  • Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer N Engl J Med. 2023 Jun 3. doi: 10.1056/NEJMoa2302983. Online ahead of print.

    2023.07.4 | 抄読会論文
    抄読会要旨 猿渡功一...
  • Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer

    2023.05.8 | 抄読会論文
    抄読会要旨 御任玲美...
  • A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy

    2023.05.8 | 抄読会論文
    抄読会要旨 猪山慎治...
  • Comparative effectiveness of omalizumab, mepolizumab, and dupilumab in asthma: A target trial emulation. J Allergy Clin Immunol. 2023 Feb 3:S0091-6749(23)00144-6.

    2023.04.24 | 抄読会論文
    抄読会要旨 穴井盛靖...
  • Dupilumab increases aspirin tolerance in NSAID exacerbated respiratory disease (N-ERD) Schneider S, et.al: Eur Respir J. 2022;in press

    2023.04.21 | 抄読会論文
    抄読会要旨 吉田知栄子...
Copyright© 2024 熊本大学大学院生命科学研究部 呼吸器内科学分野 All rights reserved.